Novanta (NOVT) Q4 2025 earnings review
Growth Returns, But Cash Flow Collapses Under Supply Chain Shifts
Novanta delivered a strong top-and-bottom-line finish to 2025, returning to positive organic growth (+2.2%) in Q4 and driving Adjusted EBITDA up 17%. Customer bookings surged 25% with a 1.11x book-to-bill, signaling an accelerating demand environment heading into 2026. However, this growth came at a severe cost to liquidity. Operating Cash Flow plunged 86% YoY to just $8.8M in Q4, and fell 60% for the full year. Management cited 'temporary increases in net working capital' tied to regionalizing manufacturing to dodge trade disruptions. While the forward outlook is bullish, the massive divergence between rising profits and evaporating cash requires close monitoring.
🐂 Bull Case
A 25% jump in Q4 customer bookings and a 1.11x book-to-bill ratio validate management's narrative of a sequentially improving demand environment across key target markets.
Despite cash flow noise, the balance sheet remains strong with Net Debt at a negative ($121M) after recent capital raises. Management claims they have 'the largest acquisition pipeline in the company's history'.
🐻 Bear Case
The 60% full-year drop in operating cash flow ($64M vs $158M prior year) directly contradicts the 5% growth in Adjusted EBITDA. Tying up capital in inventory to build 'regional resilience' is an expensive defensive maneuver.
The regionalized manufacturing initiative is expected to conclude by the end of 26Q2. Until then, gross margins and working capital remain vulnerable to friction and transition costs.
⚖️ Verdict: ⚪
Cautiously Bullish. The return to organic growth and the massive bookings surge are exactly what the market wanted to see. However, the severe cash flow burn limits the grade until working capital normalizes in late 2026.
Key Themes
Bookings Momentum Points to 2026 Acceleration
After quarters of volatile order patterns, customer bookings accelerated dramatically, up 25% in Q4 with an overall book-to-bill of 1.11x. This reverses the 0.88 book-to-bill seen in Q1 and provides hard data backing the mid-single-digit organic growth guidance for 2026.
Operating Cash Flow Collapse
This is the most glaring contradiction in the report. Adjusted EBITDA grew 17% in Q4, but Operating Cash Flow cratered 86% YoY to $8.8M. For the full year, OCF dropped from $158.5M to $64.1M. Management attributes this to a deliberate 'strategy to regionalize manufacturing' causing temporary working capital spikes. While strategic, it is a severe drag on liquidity.
Physical AI and Robotics
A major underlying driver for the Automation segment is the adoption of 'Physical AI'. Novanta is capitalizing on warehouse automation and humanoid robotics, providing the critical sensing and motion control subsystems. Earlier this year, they secured a $50M contract with a leading e-commerce player, cementing this as a highly visible multi-year growth engine.
Macro: Tariffs and Trade Disruptions Forcing Costly Pivots
The entire cash flow issue stems from global trade friction. U.S.-China tariff threats previously put tens of millions of revenue at risk, forcing Novanta into a rapid 'in-region for-region' manufacturing shift. While management states this will be 'largely completed by the end of the second quarter of 2026', it represents a massive logistical distraction that compresses near-term cash conversion.
Medical Innovation Outpacing Laggard Markets
Despite persistent headwinds in life sciences and precision medicine (which dragged down growth in prior quarters), the overarching shift toward less cyclical medical end markets is working. High-teens growth in Advanced Surgery products, like next-gen smoke evacuating insufflators, continues to anchor the company's margin profile.
Other KPIs
Accelerating. Up 17% YoY. The Adjusted EBITDA margin reached 23.5%, a robust expansion from 21.9% in 24Q4, proving that despite supply chain and working capital headaches, the core pricing power and product mix shift are highly margin-accretive.
Reversing. Driven by a $614.4M capital raise (tangible equity units), cash and equivalents ballooned to $380.9M. Total debt sits at $250.8M. This massive liquidity injection completely de-risks the balance sheet from the operational cash flow burn and fully funds the 'largest acquisition pipeline in the company's history'.
Guidance
Accelerating. The $1.04B midpoint implies ~6.1% YoY growth, a clear step up from the 3.3% reported growth in FY25. This aligns with management's expectation of mid-single-digit organic growth.
Accelerating. The $3.575 midpoint implies 8.7% YoY growth, outpacing revenue growth and demonstrating continued operating leverage, even as they absorb the final costs of the manufacturing footprint realignment.
Reversing. The midpoint of $165M implies a massive 157% YoY rebound from FY25's dismal $64.1M. This confirms management's view that the current working capital build is strictly temporary and will unwind heavily in the second half of 2026.
Accelerating YoY, but Decelerating sequentially. The $252.5M midpoint implies 8.2% YoY growth compared to 25Q1, but a slight -2.2% drop from the strong 25Q4 finish, likely reflecting standard industrial seasonality.
Key Questions
Working Capital Unwind Timing
Operating cash flow guidance for FY26 implies a massive recovery ($165M midpoint). Exactly what quarter do you expect the inventory built for the regionalization strategy to start unwinding and turning into cash?
M&A Pipeline Specifics
You now have a negative net debt position and cite the 'largest acquisition pipeline' in history. Are you prioritizing software-centric recurring revenue assets like the recent Keonn deal, or traditional hardware tuck-ins?
Precision Medicine Stabilization
Throughout 2025, life sciences and precision medicine were cited as primary headwinds. With 25% overall bookings growth in Q4, have you finally seen a definitive bottom in biotech and pharma CapEx?